(4aS,8aR)-NPD-001 是一种有效的DNMT3A的变构抑制剂。(4aS,8aR)-NPD-001 通过破坏蛋白质-蛋白质相互作用来抑制 DNMT3A 的活性。(4aS,8aR)-NPD-001 可诱导急性髓系白血病 (AML) 细胞凋亡 (apoptosis)。(4aS,8aR)-NPD-001 诱导不同的 AML 细胞系分化，包括 DNMT3A R882 突变的细胞。
| 生物活性 | (4aS,8aR)-NPD-001 is a potent and allosteric inhibitor ofDNMT3A. (4aS,8aR)-NPD-001 inhibits DNMT3A activity by disrupting protein-protein interactions. (4aS,8aR)-NPD-001 inducesapoptosisof acute myeloid leukemia (AML) cell lines. (4aS,8aR)-NPD-001 induces differentiation of distinct AML cell lines including cells with mutated DNMT3A R882[1]. |
| IC50& Target | |
体外研究
(In Vitro) | (4aS,8aR)-NPD-001 (compound 2) (60 μM) disrupts DNMT3A-DNMT3L interactions at the DNMT3A tetramer interface, inhibits the stimulation of DNMT3A_WT activity by DNMT3L, but does not inhibit the activation of DNMT3A_WT by H3 peptides[1].
(4aS,8aR)-NPD-001 (0-120 μM, 100 min) inhibits the activation of DNMT3A_R882H by DNMT3L[1].
(4aS,8aR)-NPD-001 (0-30 μM, 72 h) induces apoptosis and and differentiation in AML cell lines in a concentration-dependent manner[1].
(4aS,8aR)-NPD-001 (5 μM, 20 days) leads to a time-dependent decrease of global 5-methylcytosine[1].
Apoptosis Analysis[1] | Cell Line: | Human AML cell lines | | Concentration: | 0, 1, 5, 10, 20, and 30 μM | | Incubation Time: | 72 h | | Result: | Showed a dose-response effect with a marked increase in apoptosis in the 7-12 μM range. Led to a concentration-dependent increase in the myeloid differentiation marker, CD11b, in multiple PI-negative AML cell lines: MV411 (biphenotypic B myelomonocytic leukemia), MOLM13 (acute monocytic leukemia), THP-1 (acute monocytic leukemia), OCI-AML3 (DNMT3A R882 mutant, AML), KASUMI (acute myeloblastic leukemia), HL60 (acute promyelocytic leukemia), and K562 (chronic myelogenous leukemia). |
|
| 分子量 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com